SYNTA66

SYNTA66

Application

Synta66 has been used:as a Ca2+release-activated calcium (CRAC) channel inhibitor to study its effects on ORAI isoformsas an ORAI1 blocker to study its effects on the entry of Ca2+ in chronic lymphocytic leukemia (CLL) B cellsas a CRAC blocker to study its effects on the influx of Ca2+ by store-operated Ca2+entry (SOCE) in enamel cells

Biochem/physiol Actions

Synta66 (S66) is a CRAC (Ca2+ release-activated Ca2+) channel inhibitor that blocks SOCE (store-operated Ca2+ entry) upon Ca2+ depletion from intracellular stores by thapsigargin in human vascular smooth muscle cells (VSMCs) with high potency (IC50 = 26 nM & 43 nM based on maximum Ca2+ level & rate of increase, respectly). Synta66 exhibits no affinity toward a range of receptors and ion channels (e.g. L-type Ca2+ channel) and does not affect TRPC1/5-mediated SOCE or store-operated non-selective cationic current. Leukocytes are reported to be less sensitive to CRAC inhibition by Synta66 (IC50 = 1.76 µM/HL-60, 1 ?M/Jurkat, 1.4 µM/rat RBL).

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575602 SYNTA66 white to beige 100 SIGMA-ALDRICH 2-8°C DMSO: 20 mg/mL, clear powder ≥98% (HPLC)
£484.71 (exc VAT) per 25MG
-
+
3575603 SYNTA66 white to beige 100 SIGMA-ALDRICH 2-8°C DMSO: 20 mg/mL, clear powder ≥98% (HPLC)
£150.43 (exc VAT) per 5MG
-
+